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We read with great interest the letter by Ustungad et al. The main issue they 
raise is about the mechanism underlying the beneficial effects of non-selective 
beta-blockers (NSBB) in the observed reduction in mortality of patients with 
acute on chronic liver failure (ACLF) [1]. We agree with Ustungad and 
colleagues that the hypothesis that the mechanism of beneficial effects is 
through reduction in bacterial translocation is hypothetical. However, the 
significant differences in the white cell count between those patients that were 
treated with NSBB and those that were not is certainly supportive of the 
hypothesis but we completely agree that this needs to be verified in 
prospective studies. 
 
The second point they raise is about potential confounders. Active alcoholism, 
platelet count and previous decompensations and in particular, GI bleeding, 
cannot really be considered as potential confounders. All of these were 
associated with the use of NSBB (Table 1), but none were associated with 
differences in mortality rates (Table 3) [1]. By definition, a potential 
confounder must show a clear association with both the outcome and the 
factor, which is obviously not the case here. Despite this, the multivariate 
analysis included both previous decompensations and active alcoholism in the 
previous 3 months, since they were the only two factors showing an 
imbalance between NSBB and non-NSBB groups (together with age). Platelet 
count was not considered for this purpose since lab parameters and the 
evaluation of organ failures, scores and ACLF grades were taken at patients' 
enrolment, so they can be considered as the effect of being treated with 
NSBB during the previous 3-months. 
 The authors rightly suggest that the CLIF-C ACLF score is the best-validated 
scoring system for patients with ACLF [2]. The data presented in our paper 
helps to understand the score better. As is illustrated in Figure 3, the 
predicted mortality of ACLF patients for a given CLIF-C ACLF score between 
the patients treated with NSBB or not was best differentiated between the 
score values of about 30-60 indicating that at CLIF-C ACLF score of <30 or 
>60, the discriminating value of the score is limited and new biomarkers are 
needed to provide better discrimination [1]. Nevertheless, as Ustungad et al. 
suggest, NSBB use should be accounted for when judging the predictive 
value of the CLIF-C ACLF score.  
 
Finally, there were no statistically significant differences between the use of 
lactulose (NSBB 61.1%; No NSBB 52.2%; p=0.1), Rifaximin (NSBB 17.2%; 
No NSBB 11.7%; p=0.16) or norfloxacin (NSBB 4.4%; No NSBB 2.4%; 
p=0.61) between the groups treated or not treated with NSBBs. 
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